Page 2089 - Williams Hematology ( PDFDrive )

2064 Part XII: Hemostasis and Thrombosis Chapter 120: Hereditary Qualitative Platelet Disorders 2065

81. Ward CM, Chao YL, Kato GJ, et al: Substitution of Asn, but not Tyr, for ASP119 of the 108. Chen YP, O’Toole TE, Ylanne J, et al: A point mutation in the integrin beta 3 cyto-
β3 integrin subunit preserves fibrin binding and clot retraction. Blood 90:26a, 1997. plasmic domain (S752—>P) impairs bidirectional signaling through alpha IIb beta 3
82. Fournier DJ, Kabral A, Castaldi PA, Berndt MC: A variant of Glanzmann’s throm- (platelet glycoprotein IIb-IIIa). Blood 84:1857–1865, 1994.
basthenia characterized by abnormal glycoprotein IIb/IIIa complex formation. Thromb 109. Coventry A, Bull-Otterson LM, Liu X, et al: Deep resequencing reveals excess rare
Haemost 62:977–983, 1989. recent variants consistent with explosive population growth. Nat Commun 1:131, 2010.
83. Newman PJ, Weyerbusch-Bottum S, Visentin GP, et al: Type II Glanzmann throm- 109A. Buitrago L, Rendon A, Liang Y, et al: αIIbβ3 variants defined by next-generation
basthenia due to a destabilizing amino acid substitution in platelet membrane glyco- sequencing: Predicting variants likely to cause Glanzmann thrombasthenia. Proc Natl
protein IIIa. Thromb Haemost 69:1017, 1993. Acad Sci U S A E1898–E1907, 2015.
84. Lanza F, Stierle A, Fournier D, et al: A new variant of Glanzmann’s thrombasthenia 110. Rosenberg N, Hauschner H, Peretz H, et al: A 13-bp deletion in alpha(IIb) gene is a
(Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and founder mutation that predominates in Palestinian-Arab patients with Glanzmann
a glycoprotein IIIa Arg214Trp mutation. J Clin Invest 89:1995–2004, 1992. thrombasthenia. J Thromb Haemost 3:2764–2772, 2005.
85. D’Andrea G, Bafunno V, Del VL, et al: A beta3 Asp217—>Val substitution in a patient 111. Fiore M, Pillois X, Nurden P, et al: Founder effect and estimation of the age of the
with variant Glanzmann Thrombasthenia severely affects integrin alphaIIBbeta3 func- French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche
tions. Blood Coagul Fibrinolysis. 19:657–662, 2008. families. Eur J Hum Genet 19:981–987, 2011.
86. Baker EK, Tozer EC, Pfaff M, et al: A genetic analysis of integrin function: Glanzmann 112. Coller BS, Seligsohn U, Zivelin A, et al: Immunologic and biochemical characteriza-
thrombasthenia in vitro. Proc Natl Acad Sci U S A 94:1973–1978, 1997. tion of homozygous and heterozygous Glanzmann’s thrombasthenia in Iraqi-Jewish
87. Ward CM, Kestin AS, Newman PJ: A Leu262Pro mutation in the integrin beta(3) sub- and Arab populations of Israel: Comparison of techniques for carrier detection. Br J
unit results in an alpha(IIb)-beta(3) complex that binds fibrin but not fibrinogen. Blood Haematol 62:723–735, 1986.
96:161–169, 2000. 113. Shpilberg O, Rabi I, Schiller K, et al: Patients with Glanzmann thrombasthenia lacking
88. Loftus JC, Halloran CE, Ginsberg MH, et al: The amino-terminal one-third of alpha platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are
IIb defines the ligand recognition specificity of integrin alpha IIb beta 3. J Biol Chem not protected from atherosclerosis. Circulation 105:1044–1048, 2002.
271:2033–2039, 1996. 114. Cronberg S, Nilsson IM, Zetterqvist E: Investigation of a family with members with
89. Springer TA: Folding of the N-terminal, ligand-binding region of integrin α-subunits both severe and mild degree of thrombasthenia. Acta Paediatr Scand 56:189–197, 1967.
into a β-propeller domain. Proc Natl Acad Sci U S A 94:65–72, 1997. 115. Stormorken H, Gogstad GO, Solum NO, Pande H: Diagnosis of heterozygotes in
90. Ruan J, Peyruchaud O, Alberio L, et al: Double heterozygosity of the GPIIb gene in a Glanzmann’s thrombasthenia. Thromb Haemost 48:217–221, 1982.
Swiss patient with Glanzmann’s thrombasthenia. Br J Haematol 102:918–925, 1998. 116. Coller BS, Peerschke EI, Scudder LE, Sullivan CA: A murine monoclonal antibody that
91. Wilcox DA, Paddock CM, Lyman S, et al: Glanzmann thrombasthenia resulting from a completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-
single amino acid substitution between the second and third calcium-binding domains like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest
of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. J Clin 72:325–338, 1983.
Invest 95:1553–1560, 1995. 117. Malmsten C, Kindahl H, Samuelsson B, et al: Thromboxane synthesis and the plate-
92. Wilcox DA, Wautier JL, Pidard D, Newman PJ: A single amino acid substitution flank- let release reaction in Bernard- Soulier syndrome, thrombasthenia Glanzmann and
ing the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb Hermansky-Pudlak syndrome. Br J Haematol 35:511–520, 1977.
beta 3 integrin complex. J Biol Chem 269:4450–4457, 1994. 118. Charo IF, Feinman RD, Detwiler TC: Interrelations of platelet aggregation and secre-
93. Basani RB, Vilaire G, Shattil SJ, et al: Glanzmann thrombasthenia due to a two amino tion. J Clin Invest 60:866–873, 1977.
acid deletion in the fourth calcium-binding domain of alpha IIb: Demonstration of the 119. Heptinstall S, Taylor PM: The effects of citrate and extracellular calcium ions on the
importance of calcium-binding domains in the conformation of alpha IIb beta 3. Blood platelet release reaction induced by adenosine diphosphate and collagen. Thromb
88:167–173, 1996. Haemost 42:778–793, 1979.
94. Kiyoi T, Tomiyama Y, Honda S, et al: A naturally occurring Tyr143His alpha IIb muta- 120. Caen JP, Cronberg S, Levy-Toledano S, et al: New data on Glanzmann’s thrombasthenia.
tion abolishes alpha IIb beta 3 function for soluble ligands but retains its ability for Proc Soc Exp Biol Med 136:1082–1086, 1971.
mediating cell adhesion and clot retraction: Comparison with other mutations causing 121. Zucker MB, Vroman L: Platelet adhesion induced by fibrinogen adsorbed onto glass.
ligand-binding defects. Blood 101:3485–3491, 2003. Proc Soc Exp Biol Med 131:318–320, 1969.
95. Basani RB, French DL, Vilaire G, et al: A naturally-occurring mutation near the amino 122. Stanford MF, Munoz PC, Vroman L: Platelets adhere where flow has left fibrinogen on
terminus of α defines a new region involved in ligand binding to α β . Blood 95: glass. Ann N Y Acad Sci 416:504–512, 1983.
IIb 3
IIb
180–188, 2000. 123. Zucker MB, McPherson J: Reactions of platelets near surfaces in vitro: Lessons from the
96. Westrup D, Santoso S, Becker-Hagendorff K, et al: Transfection of GPIIbIIe176/IIIa platelet retention test. Ann N Y Acad Sci 283:128, 1977.
(Frankfurt I) in mammalian cells. Thromb Haemost 77:671, 1997. 124. Bevers EM, Comfurius P, Nieuwenhuis HK, et al: Platelet prothrombin converting
97. Honda S, Tomiyama Y, Shiraga M, et al: A two-amino acid insertion in the Cys146- activity in hereditary disorders of platelet function. Br J Haematol 63:335–345, 1986.
Cys167 loop of the α subunit is associated with a variant of Glanzmann thrombasthe- 125. Reverter JC, Beguin S, Kessels H, et al: Inhibition of platelet-mediated, tissue factor-
IIb
nia. J Clin Invest 102:1183–1192, 1998. induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential
98. Kirchmaier CM, Westrup D, Becker-Hagendorff K, et al: A new variant of Glanzmann implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical
thrombasthenia (Frankfurt I). Thromb Haemost 73:1058, 1995. restenosis.” J Clin Invest 98:863–874, 1996.
99. Grimaldi CM, Chen F, Wu C, et al: Glycoprotein IIb Leu214Pro mutation produces 126. Beguin S, Kumar R, Keularts I, et al: Fibrin-dependent platelet procoagulant activity
Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in requires GPIb receptors and von Willebrand factor. Blood 93:564–570, 1999.
GPIIb/IIIa. Blood 91:1562–1568, 1998. 127. Gemmell CH, Sefton MV, Yeo EL: Platelet-derived microparticle formation involves
100. Fullard J, Murphy R, O’Neill S, et al: A Val193Met mutation in GPIIIa results in a glycoprotein IIb- IIIa. Inhibition by RGDS and a Glanzmann’s thrombasthenia defect. J
GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. Br J Haematol Biol Chem 268:14586–14589, 1993.
115:131–139, 2001. 128. Nomura S, Komiyama Y, Matsuura E, et al: Participation of α IIb β 3 in platelet
101. Ruiz C, Liu CY, Sun QH, et al: A point mutation in the cysteine-rich domain of microparticle generation by collagen plus thrombin. Haemostasis 26:31–37, 1996.
glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) inte- 129. Nomura S, Komiyama Y, Murakami T, et al: Flow cytometric analysis of surface mem-
grin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like brane proteins on activated platelets and platelet-derived microparticles from healthy
phenotype. Blood 98:2432–2441, 2001. and thrombasthenic individuals. Int J Hematol 58:203–212, 1993.
102. Vanhoorelbeke K, De Meyer SF, Pareyn I, et al: The novel S527F mutation in the integ- 130. Byzova TV, Plow EF: Networking in the hemostatic system. Integrin alphaiibbeta3
rin beta3 chain induces a high affinity alphaIIbbeta3 receptor by hindering adoption of binds prothrombin and influences its activation. J Biol Chem 272:27183–27188, 1997.
the bent conformation. J Biol Chem 284:14914–14920, 2009. 131. Byzova TV, Plow EF: Activation of alphaVbeta3 on vascular cells controls recognition
103. Chen YP, Djaffar I, Pidard D, et al: Ser-752—>Pro mutation in the cytoplasmic domain of prothrombin. J Cell Biol 143:2081–2092, 1998.
of integrin β 3 subunit and defective activation of platelet integrin α IIb β 3 (glyco- 132. Tschopp TB, Weiss HJ, Baumgartner HR: Interaction of thrombasthenic platelets with
protein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A subendothelium: Normal adhesion, absent aggregation. Experientia 31:113–116, 1975.
89:10169–10173, 1992. 133. Sakariassen KS, Nievelstein PFEM, Coller BS, Sixma JJ: The role of platelet membrane
104. Ylanne J, Chen Y, O’Toole TE, et al: Distinct functions of integrin α and β subunit glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium.
cytoplasmic domains in cell spreading and formation of focal adhesions. J Cell Biol Br J Haematol 63:681–691, 1986.
122:223–233, 1993. 134. Weiss HJ, Turitto VT, Baumgartner HR: Platelet adhesion and thrombus formation on
105. Wang R, Shattil SJ, Ambruso DR, Newman PJ: Truncation of the cytoplasmic domain subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules.
of β3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the Blood 67:322, 1986.
integrin α β3 complex. J Clin Invest 100:2393–2403, 1997. 135. Weiss HJ, Turitto VT, Baumgartner HR: The role of shear rate and platelets in promoting
IIb
106. Chen YP, Djaffar I, Pidard E: Ser752Pro mutation in the cytoplasmic domain of integrin fibrin formation on rabbit subendothelium: Studies utilizing patients with quantitative
β subunit and defective activation of platelet integrin α β (glycoprotein IIb-IIIa) in and qualitative platelet defects. J Clin Invest 78:1072–1082, 1986.
3
IIb 3
a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A 89:10169–10173, 136. Harrison P, Robinson M, Liesner R, et al: The PFA-100: A potential rapid screening tool
1992. for the assessment of platelet dysfunction. Clin Lab Haematol 24:225–232, 2002.
107. Ylanne J, Huuskonen J, O’Toole TE, et al: Mutation of the cytoplasmic domain of the 137. Buyukasik Y, Karakus S, Goker H, et al: Rational use of the PFA-100 device for screen-
integrin beta 3 subunit. Differential effects on cell spreading, recruitment to adhesion ing of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis
plaques, endocytosis, and phagocytosis. J Biol Chem 270:9550–9557, 1995. 13:349–353, 2002.

Kaushansky_chapter 120_p2039-2072.indd 2064 9/21/15 2:22 PM